China (Wuhan) Exhibition on Pharmaceutical Excipients and Functional Food IngredientsPHARMEX

The China Wuhan Pharmaceutical Excipients and Functional Food Ingredients Exhibition (PHARMEX) is one of the premier events in China’s pharmaceutical excipients industry, playing a pivotal role in the evaluation of generic drug consistency. Guided by a commitment to craftsmanship and relentless pursuit of excellence, Chinese excipient manufacturers have long upheld the belief that providing high-quality, efficient, stable‑performing, and competitively priced excipients will help secure China’s position as a global leader in pharmaceutical manufacturing.

During this edition of the exhibition, the pharmaceutical excipients sector will be centered around two core themes—“full‑chain collaboration” and “technological breakthroughs”—driving comprehensive content showcases that span the entire value chain, from R&D and quality control through production to regulatory review. The event will bring together senior R&D, QA, and procurement executives from over 5,000 domestic companies engaged in generic drugs, improved new drugs, and biologics, facilitating precise matchmaking to ensure that every tablet, injection, and inhalation formulation begins with optimal excipient selection—thereby accelerating China’s pharmaceutical industry’s transition from “catching up” to “leading” on the global stage.

In 2025, the number of innovative drug approvals is expected to reach yet another record, as China’s pharmaceutical sector continues to focus on three key pillars: formulation innovation, consistency evaluation, and internationalization. In this context, pharmaceutical excipients have evolved from supporting players to critical enablers that determine both product quality and lifecycle performance. Consistency evaluations and dual submissions to both Chinese and U.S. regulatory authorities have elevated excipients to center stage: sustained‑release matrix systems can make or break bioequivalence outcomes; lipid‑based phospholipids influence the toxicity window of ADCs; and lactose micronized powders for inhalation formulations directly impact pulmonary deposition rates. As such, pharmaceutical excipients have transformed from ancillary components into architects of quality and safety. Nevertheless, 90% of high‑end excipients remain imported, leaving an enormous untapped market opportunity worth hundreds of billions of yuan for domestic substitution.

At the China Wuhan Pharmaceutical Excipients and Functional Food Ingredients Exhibition (PHARMEX), leading domestic and international excipient manufacturers, along with tens of thousands of pharmaceutical R&D professionals and seasoned procurement specialists, will converge to further enhance the quality and efficacy of Chinese medicines.